Obesity
51 articles on Obesity, written by Shotlee and medically reviewed for clinical accuracy.
Retatrutide: A New Era in Weight Loss Drugs vs. Ozempic
Eli Lilly's experimental drug retatrutide has demonstrated unprecedented weight loss results in a pivotal trial. This article delves into its mechanisms, efficacy, safety, and how it stacks up against current leading weight loss medications like Ozempic and Wegovy.
6 min read
New Procedure May Combat Weight Regain After GLP-1s
Losing weight with GLP-1 medications like semaglutide and tirzepatide is a significant achievement, but maintaining that loss after stopping treatment presents a major challenge. A new experimental procedure, duodenal mucosal resurfacing (DMR), is showing remarkable potential in helping individuals keep the pounds off.
7 min read
Study: Semaglutide Does Not Raise NAION Risk in Obesity, Diabetes
A large study presented in San Diego reveals semaglutide use is not associated with higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with overweight or obesity. In fact, it lowered NAION risk by 64% among those with type 2 diabetes compared to non-GLP-1 therapies. Experts emphasize continued monitoring of blood sugar and blood pressure.
5 min read
Experts Stress Holistic Approach to Semaglutide for Weight Management
At a recent Pune meeting, experts from Pune and Mumbai underscored a holistic framework for Semaglutide use in weight management, especially as the drug goes off-patent in India. They stress pairing it with diet, exercise, and thorough patient assessments for lasting results in obesity and diabetes control. Generic versions now available for Rs 1,290 per month offer affordable access with proper precautions.
6 min read
New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise
Lab mice shed pounds when key amino acids—methionine and cysteine—were cut from their diet, igniting fat burning without exercise. A University of Southern Denmark study shows this diet-induced thermogenesis boosted calorie burn by 20%, nearly matching constant cold exposure. This could redefine obesity treatments beyond GLP-1 drugs.
6 min read
Coverage Unlocks Semaglutide's Potential for Obesity & Diabetes
Semaglutide, a powerful GLP-1 receptor agonist, transforms obesity and diabetes management but requires robust insurance coverage to deliver full benefits. Gasoyan and Rothberg emphasize access hurdles like prior authorizations that delay treatment. Addressing these ensures equitable health improvements amid rising metabolic disorders.
2 min read
Ozempic's Rise: GLP-1 Drugs Curbing US Obesity Rates
CDC 2024 data shows US obesity rates dipping for the first time in decades, thanks to Ozempic and GLP-1 drugs. Originally a diabetes treatment, these medications mimic GLP-1 hormones for dramatic weight loss. Learn the serendipitous science behind them and their broader implications.
2 min read
Doctor: You May Regain Weight After Stopping GLP-1 Drugs
Doctor Karan Rajan explains why you might regain weight after quitting GLP-1 drugs: they mimic treatments for chronic conditions like high blood pressure. Obesity requires ongoing management with lifestyle factors like diet, exercise, and sleep. Not everyone needs GLP-1s forever, but stopping without changes risks relapse.
1 min read
Understanding GLP-1 Drugs for Weight Loss & Diabetes
GLP-1 drugs mimic natural hormones to reduce hunger, slow digestion, and control blood sugar, aiding weight loss and type 2 diabetes. In Malaysia, over 54% of adults are overweight or obese, prompting Health Ministry rollout for vulnerable groups in 2026. Understand benefits, risks, and safe use guidelines.
3 min read
Prof Urges Caution on Funding Wegovy Rollout
Prof Jim Mann cautions against broad funding for Wegovy, urging focus on high-risk patients like those with heart disease or diabetes. He emphasizes integrating GLP-1 medications into a national obesity strategy with mandatory nutritional support to prevent weight regain. Early data highlights side effect risks and the need for dietary counseling.
2 min read
Specialist: Funding Wegovy Saves Taxpayer Money Long-Term
Pharmac is evaluating funding for Wegovy, a GLP-1 receptor agonist, to combat New Zealand's high obesity rates. Weight loss specialist Dr. Gerard McQuinlan says it could save taxpayers billions by preventing diseases like Type 2 diabetes. Experts weigh long-term costs, side effects, and criteria.
2 min read
Ozempic Era Over? BMJ Study on GLP-1 Weight Regain
The Ozempic hype may fade as a BMJ study shows users regain lost weight within 1.5 years after stopping GLP-1 drugs. These medications reduce appetite but require lifelong use and lifestyle changes for lasting results. Obesity stems from systemic issues like convenience culture and ultra-processed foods, not just willpower.
3 min read
Pharmac Seeks Advice on Funding Wegovy Weight Loss Drug
New Zealand faces the third-highest adult obesity rate in the OECD, prompting Pharmac to seek clinical advice on funding Wegovy. Two applications propose semaglutide for high-BMI patients with cardiovascular risks or comorbidities. Experts argue it could save billions by preventing diseases like Type 2 diabetes.
2 min read
Megyn Kelly Slams Oprah's 'Obesity Gene' as GLP-1 Cop-Out
Conservative commentator Megyn Kelly labeled Oprah Winfrey's attribution of overeating to an 'obesity gene' a cop-out. In discussions around Winfrey's book with Dr. Ania Jastreboff, GLP-1 medications are highlighted for silencing food noise. Kelly argues millions manage food thoughts without obesity through self-discipline.
2 min read
Wegovy Launches in Malaysia: Competition for Gym Memberships
Novo Nordisk's Wegovy is now available in Malaysia, offering a powerful GLP-1 option for adults with obesity or overweight conditions. With 54.4% of Malaysian adults affected, this once-weekly injection mimics gut hormones to regulate appetite. Medical experts emphasize combining it with diet, exercise, and lifestyle changes for optimal results.
2 min read
Ozempic Book Reframes Obesity Views in GLP-1 Era
A new book, 'Off the Scales,' reveals how Ozempic and GLP-1 drugs are reshaping societal views on obesity. Author Aimee Donnellan details their development, profound weight loss effects, and the urgent need for medical approaches to this growing crisis. Learn why these therapies mark a turning point in weight management.
2 min read
Obesity Medications: How They Might Transform the GLP-1 Sector
The GLP-1 market, initially dominated by weekly injections, is entering a new phase with the introduction of obesity pills. These oral options from Novo Nordisk and Eli Lilly promise greater convenience and possibly lower costs, attracting new users and reshaping the industry. Analysts predict significant market growth, with pills capturing a substantial share by 2030.
9 min read
Elderly Americans Abandon Weight-Loss Medications in Droves
Senior citizens in the U.S. often discontinue highly effective weight-loss medications such as GLP-1 drugs shortly after starting them, resulting in regained pounds and diminished health advantages. Side effects, high expenses, and inadequate insurance coverage frequently play key roles in this trend. Experts advocate for better coverage and ongoing research to address these challenges for older populations.
5 min read
Swift Weight Rebound and Erosion of Health Advantages Upon Discontinuing GLP-1s
Individuals regain their initial weight and shed all cardiometabolic improvements in less than two years following the cessation of semaglutide or tirzepatide, according to a comprehensive meta-analysis. The research underscores the rapid nature of this regain, occurring at a pace much quicker than after non-medication interventions. Experts stress the importance of sustained strategies for maintaining benefits in chronic obesity treatment.
6 min read
GLP-1 Medications Aid in Reducing Asthma Episodes in Overweight or Obese Teens
A recent study reveals that GLP-1 medications can significantly decrease severe asthma episodes among adolescents who are overweight or obese. Researchers found a notable reduction in emergency room visits and steroid use. Experts suggest these drugs offer dual benefits for weight control and asthma management.
2 min read
Wegovy Pill May Expand Access to Obesity Treatments
The United States Food and Drug Administration has greenlit the initial tablet form of a GLP-1 drug designed for shedding pounds, which might considerably broaden availability of obesity therapies. Produced by the Danish firm Novo Nordisk, this daily Wegovy pill is set to debut in early January, with clinical trial participants averaging a 16.6% drop in body weight.
1 min read
Ozempic and Weight Loss: An Examination with PhenQ Supplement Details
This article explores the use of Ozempic for weight loss, examining its effectiveness and safety. It also provides information on PhenQ as an alternative weight loss supplement.
8 min read
Novo Nordisk Receives US Approval for Oral GLP-1 Weight-Loss Medication
The FDA has approved Novo Nordisk's Wegovy as an oral medication for weight loss. This provides an alternative to injections for adults with obesity or weight-related health issues. The company anticipates a US launch in January.
2 min read
GLP-1 Medications: A Century-Long History Influences Current Discussions
The ongoing discussion regarding insurer coverage for GLP-1 medications such as Ozempic and Wegovy has reignited a familiar debate concerning the origins of illness. Some argue these weight-loss drugs are shortcuts, while others emphasize the impact of socioeconomic factors on body weight.
1 min read
newsGP - Wegovy Suggested for PBS Inclusion
Semaglutide (Wegovy) is nearing PBS inclusion for adults with cardiovascular disease and obesity, following a PBAC recommendation. The recommendation identifies specific groups to prioritize for access to GLP-1 receptor agonist medicines.
2 min read
Lilly Seeks FDA OK for Orforglipron, an Oral Weight Loss Drug | TechTarget
Eli Lilly has submitted orforglipron, its oral GLP-1 therapy, for FDA approval following successful phase 3 trial outcomes. The weight loss pill demonstrates promise in addressing weight regain issues often seen when patients discontinue GLP-1 therapy. The study showed patients maintained weight loss for up to a year.
3 min read
Why Indians Should Use Ozempic Cautiously: Understanding the Reason
With the introduction of new weight-loss and diabetes drugs like Ozempic in India, endocrinologists are emphasizing the need for cautious and medically supervised use. Concerns arise particularly for individuals with a 'thin-fat' phenotype, who may experience adverse effects.
3 min read
Ozempic-Like Drug Now Being Tested for Overweight Cats
A new medication, similar to Ozempic, is in development for overweight cats. Clinical trials suggest it could enhance quality of life and address metabolic issues like kidney disease and diabetes.
2 min read
Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs
Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.
1 min read
Clinical Trial Indicates Eli Lilly's 3-Target Drug Achieves New Weight Loss Milestone for Obesity
A novel drug candidate from Eli Lilly, targeting three metabolic pathways, has shown impressive weight loss results in a late-stage clinical trial. The study revealed an average weight loss of 28.7% among participants. However, the trial also reported a notable rate of treatment discontinuation.
3 min read
Feline Obesity Targeted by New 'Ozempic'-Like Drug Trial for Cats
A clinical trial is underway to test a new weight-loss treatment for cats using a drug class similar to Ozempic. The study, called MEOW-1, involves an implant administering medication to help overweight cats shed pounds.
3 min read
WHO Issues New Advice on GLP-1 Weight Loss Medications: Key Points
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
2 min read
Scientists Experiment with GLP-1 Drugs for Overweight Canines and Felines
A biopharmaceutical firm is planning a pilot study using GLP-1 agonists on obese cats, similar to drugs like Ozempic and Wegovy used for human weight loss. The treatment involves microchip implants that release the drug over six months. Similar trials are planned for dogs.
2 min read
Dr. Reddy's Cleared by Delhi HC to Export Semaglutide Generics of Novo Nordisk
An Indian court has granted Dr. Reddy's Laboratories Ltd permission to manufacture and export generic versions of Novo Nordisk's diabetes and obesity medications. This decision comes before the global patent expirations in 2026. The ruling allows export to countries without patent protection.
2 min read
Ozempic, a Diabetes Medication, Slated for India Launch This Month
Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.
1 min read
Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog
The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.
1 min read
Anticipating Large Profits: Ozempic Patent Expiration Sparks Indian Pharma Generics Race
With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.
7 min read
Ozempic-like Medications: New Alert Issued Over Suicidal Thought Risk
Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.
4 min read
Ozempic 2.0? Exploring the Future of Weight Loss Medications
New weight loss drugs, potentially available in oral form, are under development by Eli Lilly and Novo Nordisk. These medications aim to manage type-2 diabetes and facilitate weight loss, potentially offering a more accessible and convenient alternative to current injectables.
4 min read
Generic Drug Manufacturers Eye Price Adjustments as Novo Reduces Wegovy Costs
Following Novo Nordisk's price reduction for its Wegovy injection, generic drug manufacturers are reassessing their pricing strategies. The move comes amid increasing competition in the weight-loss drug market, with potential impacts on affordability and market share.
3 min read
Mounjaro Delivered: UAE App Introduces Weight-Loss Medication Delivery
A prominent home services company in the UAE has begun delivering weight-loss medications, indicating the sustained popularity of GLP-1 drugs. This move raises discussions about accessibility and safety when obtaining prescription drugs online.
4 min read
Ozempic 2.0 is Coming: A Potentially More Transformative Treatment
A new generation of weight loss medications is emerging, promising to be even more effective for human health. These include pills, more powerful injectables, and novel compounds that may have reduced side effects or require only monthly administration.
7 min read
Tan France of Queer Eye Tackles Obesity Stigma in Zepbound's 'Changing the Thread Collection' (Tirzepatide)
Stylist Tan France is collaborating with Lilly, the makers of Zepbound, on the 'Changing the Thread Collection,' a clothing line designed to share stories and science related to obesity. The collection aims to challenge societal biases and promote understanding of obesity as a chronic disease.
11 min read
Obesity Crisis in America Meets Ozempic Boom: Data Shows GLP-1 Hotspots
A recent report highlights the increasing use of GLP-1 medications like Ozempic and Mounjaro across the United States, with some states showing greater adoption than others. The data suggests a correlation between obesity rates and GLP-1 prescription rates, particularly in the South and Midwest.
3 min read
Novo Nordisk Stock: Factors Contributing to This Week's Decline | The Motley Fool
Shares of Novo Nordisk have decreased substantially. This drop is influenced by increased competition in the GLP-1 market and a revised outlook for future growth. The global drugmaker faces headwinds from competitors like Eli Lilly.
2 min read
Mounjaro Weight-Loss Injection Now Top-Selling Drug in India
According to recent data, Mounjaro, a drug for obesity and diabetes developed by Eli Lilly, has emerged as India's top-selling pharmaceutical brand. The medication's sales have surpassed those of long-time market leader Augmentin.
3 min read
Setmelanotide Potentially Enhances Obesity Drug Response in Hypothalamic Obesity
A recent study presented at ObesityWeek suggests that setmelanotide, when used alongside GLP-1 therapy, may lead to a substantial reduction in BMI for individuals with acquired hypothalamic obesity. The research indicates that restoring melanocortin-4 receptor pathway signaling could improve response to other anti-obesity treatments.
2 min read
AstraZeneca Completes SixPeaks Bio Acquisition to Advance Obesity Treatments
AstraZeneca has completed the acquisition of SixPeaks Bio, marking a significant step in developing advanced obesity treatments. The deal involves an initial payment of $170 million, with potential milestone payments to follow, focusing on therapies that preserve muscle mass during weight loss.
3 min read
Eli Lilly Advances Amylin Obesity Drug to Late-Stage Trials After Study Shows 20% Weight Reduction
Eli Lilly is set to begin late-stage trials for its investigational amylin obesity drug following promising mid-stage study results. The trial showed the highest dose of the weekly injection, eloralintide, resulted in an average weight loss of 20.1% in obese or overweight patients over 48 weeks.
3 min read
Searching 'Weight' Can Yield Ozempic Results: A Drug Advertising Issue
A recent study highlights a potential issue in online drug advertising. Searching for terms like 'weight loss' can yield results for drugs like Ozempic, even if they are not FDA-approved for that specific purpose, raising concerns about misleading information.
3 min read
Mounjaro Approved for Sleep Apnea: A New Hope for Better Sleep
Recent approval of Mounjaro (tirzepatide) for obstructive sleep apnea (OSA) in obese individuals signifies a groundbreaking advancement. This development addresses a critical need, offering a novel pharmacological approach to a condition affecting millions.
4 min read